Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-12-2023 | Cystic Fibrosis | Case report

Tobramycin

Ototoxicity

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Madaule J, et al. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis. Journal of Cystic Fibrosis 22: 944-948, No. 5, Sep 2023. Available from: URL: https://​dx.​doi.​org/​10.​1016/​j.​jcf.​2023.​04.​002
Metadata
Title
Tobramycin
Ototoxicity
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-52135-7

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

News item

Non-serious case reports

Case report

Dexamethasone/Hydrocortisone-sodium-succinate

Case report

Finasteride

Case report

Fluconazole/Tretinoin

Case report

Rivaroxaban

Case report

Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide/vilanterol/fluticasone-furoate interaction